Last update June 26, 2022



Safe substance and/or breastfeeding is the best option.

It is a benzamide derivative, reversible inhibitor of monoamine oxidase type A used for the treatment of depression and social anxiety disorder. Oral administration in two daily doses.

It is excreted into breast milk in a clinically non-significant amount. (Buist 1998, Pons 1990)

No clinical untoward effects on the physical and psychomotor development of the infants at both short and long-term basis. (Taylor 2009, Buist 1998)

Some reports of galactorrhea and increased prolactin have been described. (Dunn 1998, Juruena 1997, Nair 1993)

Because there is less published experience with this drug than with others, an alternative known to be safer should be preferred, especially during the neonatal period and in the event of prematurity.

See below the information of this related product:

  • Maternal Depression (Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.)


Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

N06AG02 is Moclobemide in ATC Code/s.

Is written in other languages:


Main tradenames from several countries containing N06AG02 in its composition:


Variable Value Unit
Oral Bioavail. 90 %
Molecular weight 269 daltons
Protein Binding 50 %
VD 1 - 1.5 l/Kg
pKa 14.7 -
Tmax 0.3 - 1 hours
1 - 2 hours
M/P ratio 0.7 -
Theoretical Dose 0.2 - 0.8 mg/Kg/d
Relative Dose 2.5 - 5.3 %


  1. MHRA. Moclobemide. Drug Summary. 2014 Full text (in our servers)
  2. AEMPS. Moclobemida. Ficha técnica. 2011 Full text (in our servers)
  3. Taylor T, Kennedy D. Safety of moclobemide in pregnancy and lactation, four case reports. Birth Defects Research Part A- Clinical and Molecular Teratology. 2008;82:413. 2008
  4. Buist, A., Dennerstein, L., Maguire, K. P., & Norman, T. R. Plasma and human milk concentrations of moclobemide in nursing mothers. Human Psychopharmacology: Clinical and Experimental 1998;13(8):579–582.
  5. Dunn NR, Freemantle SN, Pearce GL, Mann RD. Galactorrhoea with moclobemide. Lancet. 1998 Abstract
  6. Juruena MF, Pires ML, Calil HM. Moclobemide effects on prolactin plasma levels in healthy individuals: the hormonal increase induced by a single dose is maintained during a 4-week period of drug intake. Int Clin Psychopharmacol. 1997 Abstract
  7. Nair NP, Ahmed SK, Kin NM. Biochemistry and pharmacology of reversible inhibitors of MAO-A agents: focus on moclobemide. J Psychiatry Neurosci. 1993 Abstract Full text (link to original source) Full text (in our servers)
  8. Pons G, Schoerlin MP, Tam YK, Moran C, Pfefen JP, Francoual C, Pedarriosse AM, Chavinie J, Olive G. Moclobemide excretion in human breast milk. Br J Clin Pharmacol. 1990 Abstract Full text (link to original source) Full text (in our servers)

Total visits


Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at

e-lactancia is a resource recommended by El Parto Es Nuestro of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM